Diagnos Inc.

Diagnos Inc. develops artificial intelligence-driven medical software focused on retinal imaging. Its CARA platform generates specialist-grade reports in under two seconds and is utilized in 140 clinics across 16 countries, having screened over 400,000 patients. The company targets the optical retail sector through partnerships, including a supply agreement with EssilorLuxottica, and aims to enhance public health initiatives, such as a proposed screening program for diabetics in Quebec. Diagnos operates primarily in Canada, the USA, Saudi Arabia, Algeria, and Mexico.